The association between inflammation of the male reproductive system and oligozoospermia has been frequently reported in the clinical work-up of male infertility. To improve sperm parameters in infertile patients with genital inflammation, many phytochemical and nutraceutical drugs are currently being used. However, their use is still empirical and no conclusive data have been provided about their efficacy. The treatment with steroid anti-inflammatory drugs might be useful in reducing inflammation and improving sperm parameters, thus increasing the fertility outcome. The aim of this study was to evaluate if glucocorticoid treatment improves seminal parameters in infertile oligozoospermic patients presenting signs of accessory gland inflammation at genital ultrasound. A total of 90 infertile patients were enrolled in the study. They presented normal testicular volume, normal FSH plasma levels, the presence of various degrees of oligozoospermia, associated with scrotal and trans-rectal ultrasound signs indicative of accessory gland inflammation, but negative microbiological analysis on semen and/or prostatic secretions. Patients were randomly allocated into three groups of treatment, receiving, respectively, 5, 12.5, and 25 mg daily oral Prednisone for one month. Seminal parameters were evaluated at admission and after treatment. In patients undergoing Prednisone treatment at a daily dose of 5 mg we observed a significant increase in total sperm count. At a daily dose of 12.5 mg, Prednisone treatment improved sperm concentration, total sperm count, and the percentage of sperm motility. Twenty-five mg of Prednisone led to significant improvement in all the sperm parameters, except for semen volume. These results clearly demonstrate that Prednisone treatment can significantly improve sperm parameters in a selected population of oligozoospermic patients. These findings suggest that Prednisone treatment should be considered in idiopathic oligozoospermic patients with supposed normal spermatogenesis and accessory gland inflammatory alterations, in order to improve sperm parameters and fertility outcome.
INTRODUCTION
The inflammation of the male genital glands is a very common condition in infertile men, although underestimated in the clinical practice. In fact, the association between inflammation of the male reproductive system and oligozoospermia has been frequently reported in the clinical work-up of male infertility (Comhaire et al., 1999; La Vignera et al., 2011) . Unfortunately, although it has been reported that up to 15% of male fertility disorders are related to infections or to inflammatory disorders of the accessory glands (Pellati et al., 2008) , inflammation at this site is often clinically silent. The impact of these conditions on fertility may depend on many factors: (i) the affected tract (epididymis, prostate, or seminal vescicles); (ii) the etiology (type of pathogen or non-infectious causes); (iii) the course of the disease (acute or chronic). It has been suggested that the process of inflammation may alter the fertility potential, acting through the following major mechanisms: impaired secretion of the accessory glands, obstruction of the seminal ducts, development of an inflammatory microenvironment leading to a dysregulation of spermatogenesis (Kullisaar et al., 2012; Rusz et al., 2012; Alshahrani et al., 2013) .
It is noteworthy that the diagnosis of male genital tract inflammation is difficult. In fact, the affected patients are frequently asymptomatic and semen samples or prostatic secretions are often free from bacteria (Korrovits et al., 2008) . Some specific molecular markers of inflammation have been proposed for the diagnosis, but until now they have been underestimated in clinical practice (Lotti & Maggi, 2013; Autilio et al., 2015) . The transrectal ultrasound scan (TRUS) of prostate and seminal vescicles and the scrotal ultrasound scan (US) may be used to detect and localize the inflammatory process, allowing to classify it as prostatitis, vesiculitis, epididymitis, or more complex conditions such as prostate-vesiculitis or prostate-vesiculo-epididymitis. They are useful, in addition, to distinguish between unilateral and bilateral forms (La Vignera et al., 2012a) . However, the clinical significance of these sonographic signs is still debated and in oligozoospermic infertile patients these signs are often poorly considered and rarely treated.
Even though the diagnostic process is still debated, it is wellknown that inflammation of the male genital tract has a detrimental effect on sperm quality as it reduces concentration and motility and also possibly affects the number of morphologically normal spermatozoa (La Vignera et al., 2012b) . Therefore, this condition should be considered in all cases of male infertility associated with idiopathic oligozoospermia, particularly in those patients with specific signs of inflammation at genital ultrasound scanning.
Many phytochemical and nutraceutical drugs are being currently used to improve sperm parameters in infertile patients with genital inflammation (Urman & Oktem, 2014) . However, their use is still empirical and no conclusive data have been provided about their efficacy (Showell et al., 2014) . In this context, the treatment with steroid anti-inflammatory drugs is widely used in patients affected by chronic prostatitis because of their anti-inflammatory and immune-modifying properties (Bates et al., 2007) . In a previous study short course oral prednisolone therapy was effective in relieving symptoms of patients with chronic abacterial prostatitis (Bates & Talbot, 2000) . According to these premises, we performed an observational study aimed to analyze the variations of seminal parameters in oligozoospermic patients receiving Prednisone treatment for abacterial prostate-vesiculo-epididymitis (PVE).
MATERIALS AND METHODS
A multicentric study was performed at the Unit of Andrology and Reproductive Medicine of the University of Padova (Padova, Italy), at the Division of Medical Andrology and Endocrinology of Reproduction of the University of Perugia at Saint Mary Hospital (Terni, Italy) and at the International Scientific Institute 'Paul VI' of the Catholic University (Rome, Italy).
Although patients have been randomly assigned to different dosages of Prednisone, this study is not a randomized clinical trial without a control group, but an observational study aimed to analyze the variations of seminal parameters in oligozoospermic patients receiving Prednisone treatment for abacterial prostate-vesiculo-epididymitis (PVE).
The study was approved by the Institutional Review Board and conducted in accordance with the guidelines of the Declaration of Helsinki. Informed consent was obtained from each patient.
Patients
We planned to include in the study 18-50-year-old patients seeking medical care for primary infertility, with normal testicular volume and FSH values (<8 mUI/L) and in the presence of various degrees of oligozoospermia (total sperm count <39 9 10 6 /mL), associated with scrotal US and TRUS signs of PVE and with negative microbiological analysis on semen and/or prostatic secretions (absence of growth of more than 10 3 CFU/mL of pathogenic bacteria in cultures of diluted seminal plasma and/or secretions obtained after prostatic massage). Exclusion criteria included history of cryptorchidism, orchitis, testicular torsion or trauma, hypogonadism, occupational chemical exposure, Y chromosome microdeletions, karyotype abnormalities and CFTR mutations, ultrasound testicular volume <12 mL, FSH >8 mUI/L, fever or drug use within 3 months prior to the enrolment in this study and azoospermia.
We also excluded patients with gastric disease, diabetes mellitus, and hypertension, which might represent a contraindication for Prednisone treatment.
Design of the study
A total of 90 patients fulfilled the inclusion criteria and were enrolled in the study (enrolled patients: mean age 37.9 years; range 19-48 years). Patients were randomly allocated into three groups receiving, respectively, Prednisone 5, 12.5, and 25 mg daily for one month, in a blinded manner by third part true randomization in a 1 : 1 : 1 ratio with a random number generator. Twenty-four men were allocated to the 5 mg treatment group, 28 were allocated to the 12.5 mg treatment group, and 38 to the 25 mg treatment group.
All patients underwent a complete physical and andrological examination, standard semen analysis, complete microbiological analysis (including culture for bacteria, mycoplams, and chlamydia in semen and in prostatic secretion after prostate massage) and ultrasound evaluation.
Oral Prednisone treatment was performed with daily administration at 8:00 a.m., for one month.
To clarify the effectiveness of Prednisone therapy, patients were studied at basal time and after one month of Prednisone treatment with primary outcome represented by sperm parameters.
In patients receiving 25 mg Prednisone daily, treatment was gradually reduced after the spermiogram analysis.
Semen analysis
Semen samples were collected after 2-7 days of sexual abstinence, and spermiograms were immediately performed according to WHO guidelines (World Health Organization (WHO), 2010) at admission and at the end of Prednisone treatment. Semen evaluations were performed in a blinded manner with regard to treatment.
We considered for this study the following seminal parameters: volume, pH, sperm concentration, and total sperm count in the ejaculate, sperm motility, sperm morphology.
According to WHO guidelines (World Health Organization (WHO), 2010), the concentration of leukocytes was calculated relative to that of spermatozoa by assessing fixed and Papanicolaou stained semen smears made from undiluted semen. Considering N as the number of leukocytes counted in the same number of fields as 400 spermatozoa, and S as the concentration of spermatozoa (10 6 per mL), then the concentration (C) of leukocytes (10 6 per mL) could be obtained from the following formula: C = S 9 (N/400).
US evaluation
Ultrasonography was used to identify ultrasound signs of inflammation. TRUS and scrotal US for each center was performed by the same experienced operator, blinded to patient clinical status, using a high-resolution Echo-Color-Doppler (iU22 Philips, Eindhoven, The Netherlands or Technos, Esaote) equipped with 5-12 MHz Broadband Linear and 5-9 MHz Broadband Curved Array Transducers. Intra-observer variability was estimated to be <10%. We also categorized our patients into subjects with or without PVE, according to criteria previously described by La Vignera et al., (2012a) and by Dellabella et al., (2006) .
Statistical analysis
Distribution of data was estimated by the Pearson test. As the data were normally distributed, the results are expressed as mean AE SD. Comparisons for age, BMI, and hormonal values between groups were performed by unpaired Student's t-test.
Comparisons of pre-treatment and post-treatment seminal data within the same group were performed by paired Student's t-tests. Probability (p) values of <0.05 were considered statistically significant. All analysis were performed using the SPSS 20.0 software (Florence, Italy).
RESULTS
The baseline clinical and hormonal data of patients are summarized in Table 1 . All subjects had hormonal values within the normal range.
The treatment was well tolerated in all subjects and was undergone by all patients with no significant reported side effects. Figure 1 shows examples of different prostate and seminal vesicles TRUS and scrotal US patterns in patients. A and B panels show epididymal congestion and hyperemia, respectively. C, D, E panels show prostate central zone congestion, prostate central zone hyperemia, and prostate calcification, respectively. Panel F shows seminal vescicle congestion. Table 2 summarizes the seminal parameters observed before and after Prednisone treatment in the 5, 12.5, and 25 mg treatment groups. No significant differences were observed at basal level within the treatment groups.
In the 5 mg treatment group we observed a significant improvement in the sperm concentration and total sperm count (p < 0.05). No improvements in pH, seminal volume and in the percentage of motile and morphologically normal spermatozoa were observed. However, a significant improvement was observed when considering sperm motility as the total number of motile spermatozoa (13.38 AE 14.63 9 10 6 vs. 4.00 AE 4.68 9 10 6 , p < 0.05). At a daily dose of 12.5 mg, Prednisone treatment improved sperm concentration, total sperm count and the percentage of sperm motility (p < 0.01). No significant differences were observed in seminal volume, pH, and sperm morphology.
All sperm parameters except for semen volume, showed a significant improvement after 25 mg of Prednisone daily administration (p < 0.001). In this group, the most important effect observed after treatment was related to sperm motility and morphology.
Leukocytospermia (Leukocyte concentration >10 6 /mL) was observed only in 12/90 patients and, respectively, in 3/24 patients in the 5 mg treatment group, in 5/28 patients in the 12.5 mg treatment group, and in 4/38 patients allocated in the 25 mg treatment group. Although no significative differences have been reported in leukocyte concentration after Prednisone treatment, when considering only the 12 patients with leukocytospermia, a reduction in leukocyte count was observed in all the 12 patients, and leukocyte concentration was <10 6 /mL after the treatment in 5/12 patients. Figure 2 summarizes the changes observed in the number of spermatozoa with progressive motility observed in the three treatment groups. All groups showed after the treatment a significant improvement in the count of spermatozoa with progressive motility. The 25 mg group showed the highest increase (D of increase: 18.42 AE 26.96 9 10 6 ).
DISCUSSION
Male factor is the cause of infertility in approximately 25-30% of couples, while a mixed factor is responsible for an additional 30% of cases (Agarwal et al., 2015) . Many conditions of male infertility are associated with isolated oligozoospermia or with oligozoospermia associated to other sperm abnormalities. In most cases, oligozoospermic patients are poorly investigated and are often classified as affected by idiopathic infertility (Adamopoulos, 2000) . Oligozoospermia may occur in many reproductive or systemic disorders and it is usually associated with poorer sperm motility and abnormal morphology. This condition may reflect both qualitative and quantitative defects in spermatogenesis or it may be related to partial obstruction of the seminal tract. Medical therapy for these patients is mainly empirical and frequently unsuccessful. Therefore, the management of these patients often does not take into consideration a pharmacologic treatment, and couples are directly treated with assisted reproduction.
In clinical practice, a patient presenting oligozoospermia, in the absence of infection, with normal FSH plasma levels and normal testicular volumes, is usually considered affected by idiopathic oligozoospermia and referred to assisted reproduction. However, it is thought that he could have normal spermatogenesis and that a pharmacological treatment could be effective in restoring natural fertility. In this condition, scrotal US and TRUS may help clinicians in obtaining important diagnostic information about signs of prostatitis, vesiculitis, and epididymitis. Male urogenital tract inflammation is often silent and its diagnosis may be difficult because of the lack of specific markers; nevertheless inflammation should be considered in every case of male subfertility without signs of secretive oligozoospermia and primary testicular disease. Although leukocytospermia was proposed as a diagnostic marker for accessory gland inflammation, it is not present in all cases of inflammation and leukocyte count is not accurate enough, because of the difficulty in differentiating leukocytes from immature germ cells. Moreover, leukocytes can be trapped in the inflamed gland ducts and thus are not present in ejaculated spermatozoa. As a consequence, the diagnostic value of seminal leukocytes has been questioned (Henkel et al., 2005; Kopa et al., 2005) . In our patients, in fact, a leukocyte count >10 6 /mL was reported in only 12/90 patients with semen abnormalities and ultrasound signs of inflammation, confirming the limited value of leukocytospermia as a marker of male accessory gland inflammation. On the other hand, polymorphoelastase is a protease released by activated granulocytes; it has been proposed as a marker of semen inflammation with a cut-off level of ≥230 ng/mL (Zorn et al., 2003) , but its diagnostic specificity is still too low (EggertKruse et al., 2009) . The role of many pro-inflammatory cytokines, such as interleukin (IL)-1, IL-2, IL-6, IL-8, IL-18, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma, has been intensively investigated in male accessory gland inflammation (Motrich et al., 2005; Matalliotakis et al., 2006; Seshadri et al., 2011) and their increase in seminal fluid has been often linked with poor semen quality (Eggert-Kruse et al., 2001) . The current evidence highlights a possible clinical role of IL-8 both in bacterial and abacterial inflammation (Lotti & Maggi, 2013) , although its relationship with semen parameters has not been fully clarified.
The role of zinc (Zn) as an anti-inflammatory agent has long been suggested (Rahman et al., 2005) : high and low levels of prostatic Zn are, respectively, associated with antimicrobial activities and chronic prostatitis (Cho et al., 2002; G omez et al., 2007; Yang et al., 2015) . Whether low Zn is a cause or consequence of prostate disease is not known (Gao et al., 2012) , and the regulation of Zn homeostasis has not been clearly elucidated. On the other hand, the studies related to the changes in serum zinc levels in patients affected by chronic prostatitis are rather limited (Goel & Sankhwar, 2006) .
We recently reported that soluble urokinase plasminogen activator receptor (suPAR) may represent a marker of accessory gland inflammation (Autilio et al., 2015) , although further data are needed to validate this novel marker in clinical practice.
According to these scientific evidences, clinical data and ultrasound scan represent, at present, the gold standard to investigate accessory gland inflammation in infertile patients in clinical practice (La Vignera et al., 2012a) .
We suggest that when signs of inflammation are present when performing genital ultrasound scan in infertile patients with non-secretive oligozoospermia, these patients may benefit from an anti-inflammatory treatment based on glucocorticoid administration. To the best of our knowledge, this is the first study indicating that the treatment with glucocorticoids, even at a very low dosage and for a short period of time, is able to improve sperm parameters, and in particular the total number of motile spermatozoa, in a selected group of oligozoospermic infertile patients. Furthermore, we observed a dose-dependent effect of oral Prednisone on sperm parameters. In particular, at a daily dose of 5 mg over a month, Prednisone was effective in improving the total sperm count, at 12.5 mg in improving total sperm count and sperm motility and finally the dose of 25 mg led to a significant improvement of all seminal parameters.
In particular, we verified an increase in sperm parameters after one month of treatment, in the same spermatogenic cycle, suggesting an immediate post-testicular effect of Predisone on edema and obstruction.
Our data suggest that an inflammatory process affecting the male urogenital tract, can reduce fertility by impairing all sperm parameters, even in the presence of a normal spermatogenesis, as presumed by normal FSH levels and testicular volume. As previously reported, the process of inflammation could alter the secretory patterns of the male accessory glands. These conditions would be able to promote a partial obstruction of the ejaculatory ducts (Rusz et al., 2012 ) with a significant reduction in sperm output. Moreover, the presence of an inflammatory microenvironment could induce oxidative damage to sperm cells, leading to DNA fragmentation and with a consequent impairment in sperm motility, morphology, and fertility competence (Tremellen, 2008; Kullisaar et al., 2012; Alshahrani et al., 2013; Fraczek et al., 2013; La Vignera et al., 2013) .
Data from this study clearly demonstrate that Prednisone treatment can improve sperm parameters in a selected population of oligozoospermic patients. This treatment, probably through a reduction in inflammation and edema, resulted effective in a population of infertile men with genital ultrasound alterations suggestive for accessory gland inflammation.
Our hypothesis is that Prednisone treatment may act at different levels of the male genital tract by reducing cytokine release and oxidative stress levels, as well as edema and leukocyte infiltration of ejaculatory ducts, thus improving sperm output and quality.
Despite limitations consisting in the absence of a placebo group, in the small sample size and in no information on fertility outcome of the treated patients, in the use of pathologic ultrasound classification, which is an highly subjective and not standardized method, the study shows for the first time that Prednisone treatment is effective in selected oligozoospermic infertile men. In a further study, we will evaluate the effect of this treatment on natural fertility outcome. We did not perform investigations about cytokines, zinc, oxidative stress markers or inflammation markers, although it could add significative information, and this will be the aim of further studies.
In summary, 30-days of an oral Prednisone course, starting at a daily dose of 5 mg, significantly improved the total sperm count of selected oligozoospermic patients and let to normalization of semen parameters at 25 mg daily.
